Company profile
UK company 12109297, incorporated on 17 July 2019.
Home - Nucleome
Decoding the dark matter of the human genome to deliver first-in-class precision medicinesDiscover More
Company number 12109297
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
AA | Transaction MzU0NjAwMDg3OGFkaXF6a2N4
Published 21 Sep 2026 09:31
CS01 | Transaction MzU0MjM4NTI4M2FkaXF6a2N4
Published 03 Sep 2026 13:08
SH01 | Transaction MzU0MTQwMjQ5MmFkaXF6a2N4
Published 28 Aug 2026 10:59
SH01 | Transaction MzUzODU1MDYwM2FkaXF6a2N4
Published 13 Aug 2026 17:33
Company registered at Companies House
Nucleome Therapeutics is using its dramatically enhanced understanding of how genetic variation drives disease to identify disease affected pathways and discover new drug targets for autoimmune diseases, a market worth in excess of $35bn. Its proprietary platform, combining world-leading expertise from the University of Oxford in bioinformatics, genomics and the 3D structure of chromosomes, enables it to leverage the billions of dollars that have been invested in human genome research. Previously, mining this valuable data to find new drug targets was hindered by the location of the majority (95%) of disease-associated genetic variants in DNA that does not code for proteins and is therefore difficult to study. Using machine learning and 3D chromosomal analysis, Nucleome Therapeutics is able to link these variants to the gene targets they influence, followed by validation of the targets at scale. This unique combination of computational and experimental approaches, which is applicable across all cell types and tissues, is expected to identify derisked, high quality targets across multiple diseases. Having validated the platform, the company is focused on the identification in lymphocytes of new drug targets for autoimmune disease, against which it will develop small molecule drugs. Potential in other cell types and applications such as drug repurposing will be investigated via partnership.
Nucleome Therapeutics utilises 3D genome structures with the aim of delivering genetics-based treatments.
Nucleome Limited is a spinout from the University of Oxford with patented technology that defines the 3D structure of the genome allowing us to link disease causing genetic variants located in the non-coding DNA to affected genes. This, together with our computational pipelines, powered by machine learning capabilities, and extensive molecular biology and genetic engineering expertise, forms a platform technology for novel therapeutic target discovery and development.
Nucleome Therapeutics was spun out from the University of Oxford in 2019 after a decade of foundational research, with seed investment of £5.2m from Oxford Sciences Innovation.
The company initially secured £5.2 million in seed funding from Oxford Sciences Innovation and went on to secure £37.5 million in series A funding from Pfizer ventures, M ventures (the VC arm of Merck), JJDC (the VC arm of Johnson & Johnson) and British Patient Capital.
The company is an early stage startup. It has secured £5.2 million in seed funding from Oxford Sciences Innovation. The company has considerable interest from several large pharmaceutical companies including GSK and MERK.
